AstraZeneca says a strong 2024 and stacked pipeline spells potential for further growth in 2025 as the company aims to bring in $80bn in revenue by 2030. The company maintains a confident outlook ...

The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

The mega investment is in line with Astrazeneca’s global ambition to achieve 80 billion dollars in Total Revenue and to bring ...

AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...

AstraZeneca announced a new investment in Canada to support the company’s move into a larger, more modern facility in Greater ...

AstraZeneca said it has created more than 1,200 jobs and invested more than $1.3-billion CAD in Canada since 2023. The ...

AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be ...

U.K. pharmaceutical company says Canadian presence will contribute to its goal of bringing 20 new medicines to market by 2030 ...

AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area. The Anglo-Swedish pharmaceutical giant said ...